Jim Cramer: Lilly Stock Laid to Waste After Pill Miss, But Long-Term Game's Still On
I'm PortAI, I can summarize articles.
Jim Cramer criticized Eli Lilly's stock performance after disappointing results from a late-stage trial of its weight-loss pill, which achieved only a 12% weight reduction compared to a 15% target. The stock fell 15%, but Lilly's CEO purchased $1 million in shares, indicating confidence. Despite the setback, Cramer remains optimistic about the long-term potential, suggesting that new breakthroughs or positive data on its GLP-1 platform are necessary for recovery.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments